Welcome to our dedicated page for Advanced Biomed SEC filings (Ticker: ADVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advanced Biomed Inc. SEC filings document a Nevada emerging growth company with common stock listed on Nasdaq under ADVB. The filings identify the issuer’s biotechnology focus in precision medicine and advanced diagnostics and record material events affecting its capital structure, listed security and corporate organization.
Recent 8-K and amended 8-K filings cover securities purchase agreements, an equity line of credit, a short-term loan agreement, share issuances, the 1-for-20 reverse stock split and Nasdaq minimum-bid-price correspondence. They also document director and officer changes, material definitive agreements, completed acquisition or disposition activity, amendments to charter documents, and other formal disclosures tied to governance, financing and shareholder rights.
Advanced Biomed Inc. reported an annual 10-K describing a pre-commercial precision oncology business built on a proprietary microfluidic platform and ultra‑sensitive biosensor technology for circulating tumor cell (CTC) capture, identification and single‑cell isolation. The company has completed an Initial Public Offering of 1,640,000 shares at $4.00 per share, generating approximately $5.49M net proceeds. Several products (A+Pre and AC-1000 and corresponding chips) are cleared by the NMPA, while additional instruments and four immunostaining kits are at registration application or review stages.
The filing discloses a consolidated net loss of $3,258,969 for the year and net cash used in operating activities of $5,825,055. Management states these conditions give rise to substantial doubt about going concern, and the company intends to raise additional capital, rely on forthcoming operations, and seek financial support from related parties. The company holds multiple granted patents in China, the U.S., and international PCT filings covering its chips and separation technologies, and reports progress on mass‑production trials with injection molding partners.
Advanced Biomed Inc. filed a current report describing that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform for precision medicine and drug discovery. The filing mainly serves to furnish this press release as an exhibit for investors and other stakeholders.